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Introduction
There are persistent concerns about the
influence of the pharmaceutical and de-
vice industries on the medical literature,
and particularly on the reporting of
clinical trials, which can include the
distortion of the true evidence base of
medical interventions and overestimation
of the clinical benefit of a drug used to
treat patients [1]. An especially problem-
atic issue involves the industry practice of
publishing studies prepared by hired
medical writers but signed by academic
‘‘guest authors’’ who are invited to add
their names without fulfilling authorship
criteria. In this case, ‘‘guest authorship’’ is
accompanied by ‘‘ghostwriting,’’ which
occurs when a published article fails to
acknowledge the original writer or writers’
contributions [2–4]. Ghostwriting can also
occur when an academic research group
uses a professional writer to draft an article
based on data generated by the group.
When the research group retains control
of the data and the final analysis, however,
there is less of a concern about possible
bias in the reporting of the results, and the
appropriate remedy in that case is to
report explicitly the role and contribution
of the medical writer in the article. Here,
we concentrate on ghostwriting and guest
authorship in industry-controlled research,
where several examples have revealed the
use of ghostwriters to insert concealed
marketing messages favourable to a com-
pany’s product, and the recruitment of
academics as ‘‘guest’’ authors despite not
fulfilling authorship criteria [5–9].
Commentators have condemned the
practice as unethical and unacceptable
and have discussed the harms resulting
from this form of medical ghostwriting,
recommending that journal submissions
be policed more aggressively and that the
‘‘guest authors’’ be suitably sanctioned by
journals, academic institutions, and regu-
latory agencies [1–14]. However, these
recommendations have not yet been
widely embraced by the academic institu-
tions, medical journals, and medical li-
censing organizations that would seem to
have the most at stake in curbing this
practice. Here, we discuss some of the
reasons for this lack of response and
suggest that the law may offer a solution,
given these other institutions’ failure to
impose sanctions.
Concerns about Guest
Authorship
Guestauthorship isa disturbingviolation
of academic integrity standards, which
form the basis of scientific reliability [15].
The scientific base guiding clinical practice
and decision-making is to a large degree
formed by the peer-reviewed medical
literature. Indeed, pharmaceutical sponsors
borrow the names of academic experts
precisely because of the value and prestige
attached to the presumed integrity and
independence of academic researchers. In
turn, academics receive considerable credit
for publication, thus providing an incentive
for their willingness to act as ‘‘guests.’’
In the legal setting, peer-reviewed arti-
cles are credible sources of evidence that
may be used in lawsuits to support claims
about safety and effectiveness, and hence to
determineliability[16].Industry-controlled
publications that are prepared by ghost-
writers or that use guest authorsmay distort
perceptions about current knowledge con-
cerning a product’s safety and effectiveness.
For legal purposes, publication in peer-
reviewed journals is one of the criteria that
help to make a scientific theory or method
admissible as evidence, according to the
standards set out by the United States
Supreme Court in Daubert v. Merrell Dow
Pharmaceuticals [17]. By facilitating publica-
tion in peer-reviewed journals, guest au-
thorship creates the impression that stan-
dards of academic independence and
integrity have been satisfied even when
they have not, and makes it more likely that
the research will be treated as legally
admissible even when this is inappropriate.
Publications on which academics ap-
pear as guest authors also give credibility
to these authors in the legal setting. These
articles are sometimes used to establish an
expert witness’s authority, even when the
validity of the research in the article is the
very issue under dispute. As a result, the
treatment of the guest author as a legal
expert may prevent scrutiny of the practice
that is being challenged for contributing to
serious harm. Numerous studies have
shown that industry-sponsored clinical
trials are often biased in favor of the
sponsor, sometimes in ways that can be
detected only with access to the original
data and study protocol [8,9,18–22].
Often, the manipulations that influence
the outcome are not visible to the guest
author, whose role in the study or article
may be minimal and may fall short of
authorship criteria that would require
involvement in the development and
conduct of the study, and final approval
of the paper. Thus, guest authors help
create the appearance that a study reflects
the kind of ‘‘scientific methodology’’ that is
required to render evidence admissible
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process they credentialize themselves as
expert witnesses who can speak authorita-
tively about a product’s efficacy and safety.
Curbing Ghostwriting Practices
The International Committee of Medical
Journal Editors (ICMJE), in establishing
leading standards for biomedical publica-
tions, has sought to curb inappropriate and
unethical authorship practices by requiring
that journals ask detailed questions about
what exactly each author has contributed to
an article [23]. Editors and editors’ associa-
tions have a significant interest in preserving
the integrity of their journals, and some have
detailed sanctions. For example, the World
Association of Medical Editors (WAME) says
that ghostwriting is ‘‘dishonest and unaccept-
able,’’ and recommends that on detecting the
practice,a journal should ‘‘(1) publish a notice
that a manuscript has been ghost written,
along with the names of the responsible
companies and the submitting author; (2)
alert the authors’ academic institutions,
identifying the commercial companies; (3)
provide specific names if contacted by the
popular media or government organizations;
and (4) share their experiences on the
WAME Listserve and within other forums’’
[24]. Similarly, the Committee on Publica-
tion Ethics (COPE) recommends that journal
editors ‘‘adop[t] authorship or contributor-
ship systems that promote good practice (i.e.,
so that listings accurately reflect who did the
work) and discourage misconduct (e.g., ghost
and guest authors)’’ and recommends that
when the integrity of research is corrupted,
‘‘[e]rrors, [and] inaccurate or misleading
statements must be corrected promptly and
with due prominence’’ [25].
Some journals, such as PLoS Medicine,
have called for bans on future submissions
by authors who act as guests, formal
retraction if unacknowledged ghostwriting
is discovered after publication, and report-
ing of authors’ misconduct to institutions
[26]. This may have an impact on
academics concerned about their status
and future publication options. However,
it is unclear whether journals can or even
want to monitor the practice adequately.
Some editors have stated that their
journals are not responsible for policing
authorship practices [27]. And because
medical journals may gain significant
revenue from lucrative advertisement con-
tracts and from selling reprints (including
of ghostwritten articles), which industry
may use for off-label promotion [28], it is
unlikely that medical journals will effec-
tively seek to prevent these practices.
Commentators have also called for
academic sanction [12,29]. But while sev-
eral established academics have been asso-
ciated with ghostwritten publications, no
public sanctions appear to have been
enacted for their behaviour. Various rea-
sons explain an institutional reluctance to
take this route: the guest’s role in the
ghostwritten publications may be unclear;
academic institutions may be challenged by
their dual commitments to safeguard aca-
demic integrity while also protecting their
employees against unjust accusation; and
universities in particular tend to approach
authorship questions with understandable
prudence, considering the serious potential
impact on academic careers. Academic
institutions may also be reluctant to act
because ghostwriting cases often involve
successful academics who hold positions of
powerduetotheirprestige,academicstatus,
publication record, and grant support.
Moreover, institutions may decide not to
act because the practices involved in ghost
and guest authorship may not be far removed
from other common publication practices in
academic medicine where laboratory direc-
tors, departmental chairs, and supervisors
often claim authorship on publications be-
cause of those institutional roles rather than
by standard authorship criteria [2]. Some
clinician-investigators even insist on co-au-
thorship when providing access to patients or
samples. Pursuing sanctions for ghostwritten
articles may open a Pandora’s box, leading to
scrutiny of other authorship practices in
academia, or to anxiety-laden efforts to justify
those practices [30].
Professional organizations, such as State
Medical Boards in the US, Colleges of
Physicians and Surgeons in Canada, and
the General Medical Council in the
United Kingdom, could also intervene
when evidence of guest authorship by
licensed heath care professionals is uncov-
ered, particularly if it involves outright
misrepresentation of data [1]. When a
physician falsely claims to have analyzed
and adequately reported safety and effec-
tiveness data, this can be considered a
violation of professional integrity stan-
dards and of the commitment to patients
and good health care; physicians should
know that this may impair clinical care
and endanger patients, and they should be
sanctioned accordingly [1].
However, these professional organiza-
tions have so far failed to issue serious
sanctions in the rare cases when an
organization has looked into allegations
of authorship violations [31]. The reasons
for the lack of action may include their
general inertia in reacting to new profes-
sional challenges and the fact that they
may be more preoccupied with other,
more traditional violations of professional
standards of care, violations of conflicts of
interest, and financial fraud. There has
also been much criticism of these organi-
zations for their perceived tendency to
protect the profession [32,33]. Finally, for
the same reasons as the academic institu-
tions, professional organizations may be
uncomfortable about confronting prob-
lems of guest authorship and ghostwriting
that damage their members.
In light of the lack of institutional
responses to curb the practices of ghost-
writing and guest authorship and in light
of the significance of these practices for the
legal system, we suggest that a firm legal
response is appropriate.
Legal Liability for Ghostwriting
An important starting point for a legal
response involves the ICMJE uniform
guidelines [23] and the authorship forms
Summary Points
N Ghostwriting of medical journal articles raises serious ethical and legal concerns,
bearing on the integrity of medical research and scientific evidence used in
legal disputes.
N Medical journals, academic institutions, and professional disciplinary bodies
have thus far failed to enforce effective sanctions.
N The practice of ghostwriting could be deterred more effectively through the
imposition of legal liability on the ‘‘guest authors’’ who lend their names to
ghostwritten articles.
N We argue that a guest author’s claim for credit of an article written by someone
else constitutes legal fraud, and may give rise to claims that could be pursued in
a class action based on the Racketeer Influenced and Corrupt Organizations Act
(RICO).
N The same fraud could support claims of ‘‘fraud on the court’’ against a
pharmaceutical company that has used ghostwritten articles in litigation. This
claim also appropriately reflects the negative impact of ghostwriting on the
legal system.
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those guidelines. The theories outlined
below apply specifically to journals that
require authors to complete and sign such
a form as a condition of publication. The
guidelines were designed to ensure that
authorship credit is reserved to those who
have played a significant role in the study’s
design, conduct, and analysis, and writing
of the article. The guidelines set out three
criteria, and a person seeking credit as an
author must satisfy all three:
1) Substantial contributions to concep-
tion and design, acquisition of data,
or analysis and interpretation of data;
2) Drafting the article or revising it
critically for important intellectual
content; and
3) Final approval of the version to be
published [23].
Medical journals typically require all
authors to confirm in writing that they
have satisfied these criteria. ‘‘Guest au-
thors’’ often fail both of the first two
requirements, as suggested by evidence
that has been revealed in recent class
actions involving drugs such as Vioxx
(rofecoxib), Prempro (combined estro-
gen/progestin), and Paxil (paroxetine)
[6,7,27]. For example, an individual who
reads an article and/or offers minor
comments has offered nothing substantial
under criteria 1 and 2.
The authorship requirements are
known not only to named authors but
also to readers. The warranty of author-
ship is an important factor in ascertaining
an article’s integrity and quality. To see
this, we need only ask how readers would
react to an article prefaced with a
statement that a lead author has refused
to sign (or has repudiated) the authorship
warranty, and now wishes to clarify the
contributions of an industry-based medical
writer. Such a statement would signifi-
cantly undermine the article’s credibility
[34].
Guest Authorship as Fraud
The above thought experiment, involv-
ing a guest author who admits to playing
that role, shows that a false affirmation of
authorship is an example of fraud. Fraud
occurs when a person makes a knowingly
false representation in order to acquire
something of value, and harm occurs as a
result [35]. In its basic structure, a claim of
civil fraud on this basis would take the
same form in many countries [36]. How-
ever, such a claim is more likely to yield
significant damages if numerous plaintiffs
can join together to sue in a class action,
which may be done more easily in the US
than in many other jurisdictions. We
therefore draw on US law in this section.
Here, the guest’s false claim—asserted in
the authorship warranty—induces the
journal to publish the article, and misleads
readers about the scholarly care and
scrutiny lavished on the research. The
journal gives the guest credit for an article
that may serve as a valuable credential, by
impressing academic merit committees,
grant agencies, conference organizers,
and others including judges and juries if
the guest later acts as an expert witness
[37]. Such recognition may carry reputa-
tional and financial value. Arguably, each
repetition of the false warranty (implicitly
asserted on a CV presented to any of these
audiences) is an independent fraud. The
journal loses the opportunity to publish an
article that would legitimately have satis-
fied the authorship requirements. The
subscribers lose the opportunity to read a
legitimate article, and may be led to
believe, rely on, and use data from a
fraudulent article. If the journal became
aware that the lead author was a mere
guest, and that the journal’s authorship
requirements had not been satisfied, the
journal would not publish the article.
The characterization of guest author-
ship as fraud has received limited but
important recognition in suits involving
the False Claims Act (FCA), which impos-
es liability on those who cause fraudulent
claims to be presented to the US govern-
ment [38]. For example, in Strom ex rel.
U.S. v. Scios, Inc., the US government
alleged that the defendants’ activities led to
the presentation of false Medicare claims
[39]. These activities included sponsoring
ghostwritten articles purporting to validate
off-label use of Natrecor (nesiritide) and,
through press releases and the promotion-
al efforts of sales representatives, recklessly
encouraging doctors to prescribe the drug
for uses that were not medically accepted.
Without deciding the merits, the court
held that the allegations, if proved, would
be sufficient to state a claim under the
FCA. In Strom, it appears that the
unwarranted claims made in the ghost-
written articles, rather than their fraudu-
lent authorship, helped to support the
allegations of fraud. This approach has
great potential, but it will not always be
easy to prove the falsity of ghostwritten
research.
As Strom shows, the fraud underlying
these articles cannot be attributed solely to
the guest author, who after all has
responded to an invitation. Pharmaceuti-
cal companies and medical communica-
tions agencies are well aware of the
journals’ publication requirements. Solic-
iting and facilitating fraud may amount to
conspiracy, and may incur liability on the
same grounds as the fraud itself [41]. Such
conduct may also constitute fraud under
the Racketeer Influenced and Corrupt
Organizations Act (RICO) [41]. RICO
applies to conspiracies involving at least
two prohibited acts within a 10-year
period, if those acts ‘‘have the same or
similar purposes, results, participants, vic-
tims, or methods of commission’’ [41,42].
The predicate acts for RICO liability
include mail and wire fraud, which occur
when a fraudulent statement is sent
through the mail or by email. If a guest
lends her name to two or more articles for
the same product, she may satisfy the
RICO criteria in several different ways,
because the purposes, results, participants,
and methods of commission are the same.
Civil RICO liability allows plaintiffs to
seek treble damages from those violating
the statute [41,42].
Because a journal’s readers are all
harmed by the fraud, they may sue the
guest in a civil RICO class action [43,44].
One of their harms involves the value of
the journal subscription. The subscription
price represents the value of a year’s worth
of articles that conform to the guidelines.
Readers would not willingly pay for the
fraudulent articles, as shown by the
hypothetical example of a guest author
who disclaims responsibility for author-
ship. Whether or not they read the article
in question, its publication deprives them
of the opportunity to read an article
satisfying the journal’s requirements, and
thus diminishes the value of their subscrip-
tion. The harm may be measured by
reducing the subscription price in propor-
tion to the space devoted to the ghostwrit-
ten article. If the subscription costs $100,
and the journal publishes 100 articles per
year, it could be said that each subscriber
suffers a $1 loss from a fraudulent article.
The individual loss is small, but the
aggregate loss to all subscribers may be
significant—particularly if the cost is
trebled under RICO.
In addition, some readers access articles
on a pay-per-view basis. These readers,
too, will assume that the article meets the
journal’s requirements, and they would
also be unlikely to pay if they first saw a
disclaimer of authorship responsibility.
These purchasers might constitute a dis-
tinct subclass in a RICO class action, with
damages based on the cost of the down-
load.
To prevail, the plaintiffs would not have
to prove individually that they relied on
the guest’s fraudulent claim. In 2008, the
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plaintiffs allege fraud under RICO, they
are not required to show that they relied
on the defendant’s assertions, so long as
they were harmed because someone else
relied on the fraud (such as the journal
editors) [45]. Once a plaintiff establishes
that the article was ghostwritten, and
shows that he or she paid for a subscrip-
tion or a download, she has sufficiently
established fraud, reliance, and harm for
the whole class of RICO plaintiffs.
Why should this approach be directed
against guest authors, rather than the
others who are complicit in the same
fraud? RICO fraud could be added to the
claims raised against pharmaceutical com-
panies in negligence suits, but the damages
would be low, as against those already
available in such cases. But the combina-
tion of monetary sanctions and reputa-
tional harm might deter academics, and
might also deter the medical communica-
tions agencies that design these studies and
seek impressive names for the byline. Here
is a case where the threat of liability—and
the uncertainties and distractions that it
brings—may be sufficient to discourage
those who are not normally sued for
harmful drugs, but who help to legitimate
the studies that publicize these products.
Guest-Authored Articles as ‘‘Fraud
on the Court’’
As to the pharmaceutical companies,
we propose another approach, also
grounded in fraud. Just as the integrity
of medical research is a key factor in
recognizing false authorship warranties as
fraud, the courts’ concern about the
integrity of their proceedings is key to
the doctrine of ‘‘fraud on the court.’’ This
doctrine takes a similar form in England,
Australia, Canada, India, and many other
countries [46]; we focus on US law here
because, as explained below, the doctrine
had its start in a case that involved a
ghostwritten article. A recent formulation
of the doctrine defines it as ‘‘conduct: 1)
on the part of an officer of the court; that
2) is directed to the judicial machinery
itself; 3) is intentionally false, willfully
blind to the truth, or is in reckless
disregard for the truth; 4) is a positive
averment or a concealment when one is
under a duty to disclose; and 5) deceives
the court’’ [47]. This definition would
apply to the use of ghostwritten articles
when they are cited by lawyers for those
who helped to create the articles or by
expert witnesses for those parties. Expert
witness testimony comes into court
through the agency of lawyers, who are
officers of the court. When a pharmaceu-
tical company helps to produce ghost-
written articles and its lawyers cite them
in court, the lawyers are, at the very least,
reckless about the falsehood and they
have a duty to disclose the truth. Reme-
dies for fraud on the court may include a
default judgment for the opposing party
(when the fraud is revealed during a
proceeding), nullification of a judgment or
a legal entitlement that was secured with
the aid of the fraud, and disbarment of
counsel who facilitated the fraud [48].
For a more concrete sense of the
doctrine, consider Hazel-Atlas Glass v.
Hartford-Empire Co. (1944), which seems to
be the only ghostwriting case decided by
the US Supreme Court [48]. The facts are
worth reviewing, because their significance
is easily misunderstood—and to the best of
our knowledge, the case has not been cited
by any commentators on medical ghost-
writing. In 1926, Hartford tried to patent a
method of molding glass. Faced with
skepticism from the Patent Office, Hart-
ford’s employees wrote an article lauding
their method as an important advance,
and then found an author for it in William
Clarke, president of the Flint Glass
Workers’ Union. After publishing the
article in a trade journal, Hartford cited
it in their patent application, and the
patent was granted. In 1928, Hartford
sued Hazel, a competing glass manufac-
turer, for infringing the patent, but lost at
trial. On appeal, Hartford leaned heavily
on the spurious article. Hazel doubted its
legitimacy, and interviewed Clarke, but he
refused to acknowledge the truth. The
court of appeals ruled for Hartford,
quoting from the article as evidence of
the patent’s novelty and utility. The truth
came to light 9 years later, when Hartford
disclosed its files during an antitrust action.
In 1944, the Supreme Court vacated the
prior judgment, sanctioning Hartford’s use
of the article as a fraud on the court. The
Court also nullified Hartford’s patent, and
the Hartford lawyers who had used the
spurious article were disbarred from
practice before the Patent Office [49].
In explaining why Hartford’s actions
merited sanction, the Supreme Court
offered several observations that apply
with equal force to current examples of
medical ghostwriting. The Court stated
that using spurious claims of authorship to
legitimate claims before the Patent Office
and the courts ‘‘is a wrong against the
institutions set up to protect and safeguard
the public’’ [48]. Precisely the same could
be said about ghostwritten articles pub-
lished in medical journals through false
warranties of authorship. The courts are
among the institutions wronged by such
practices, which may lead judges to treat
the ghostwritten publications as evidence
that is legally admissible according to the
Daubert requirements, as noted above [17].
Hartford argued that it was impossible to
prove that the article was responsible for
their legal victory, but the Court rejected
that argument: ‘‘Hartford’s officials and
lawyers thought the article material. They
. . . went to considerable trouble and
expense to get it published. . . . [T]hey
urged the article upon the Circuit Court
and prevailed. They are in no position
now to dispute its effectiveness’’ [48]. We
might expect pharmaceutical defendants
to minimize the evidentiary role of ghost-
written articles today, and the same
answer would be appropriate.
Ghostwritten articles are not created
and developed primarily for legal purpos-
es; rather, they are used to publicize and
market drugs. However, a restriction on
the legal use of articles to which guest
authors have added their name could
significantly diminish their overall value.
They are often used in litigation to support
the manufacturer’s arguments about a
drug’s efficacy and safety, or to establish
a record of scientific acceptance for Daubert
purposes, or to credentialize an expert
witness. Each of those uses, if attempted by
a party that had helped to create the
article, could risk sanction. The articles
could still be used to promote drugs, but if
litigation should arise, the defendant’s
arsenal of responses would be limited.
Conclusion
The false respectability afforded to
claims of safety and effectiveness through
the use of academic investigators risks
undermining the integrity of biomedical
research and patient care. This integrity
also underpins the use of scientific evi-
dence in the courtroom. Whether publi-
cations with academic guest authors are
factually accurate is irrelevant. In Hazel-
Atlas, Hartford insisted that the article’s
claims were true, attribution issues not-
withstanding. The Supreme Court found
this argument unavailing: ‘‘Truth needs no
disguise. The article, even if true, should
have stood or fallen under the only title it
could honestly have been given—that of a
brief in behalf of Hartford, prepared by
Hartford’s agents, attorneys, and collabo-
rators’’ [48]. Today, as in 1944, one might
expect the sponsors of ghostwritten articles
to treat the question of false authorship as
an insignificant detail that merits no legal
sanction. The US Supreme Court’s com-
ments provide a sufficient rebuttal to such
claims.
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